Transgene (PARIS: TNG), a biotechnology firm specializing in virus-based immunotherapies for cancer treatment, has submitted the French edition of its 2025 Universal Registration Document to the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, bearing the identification number D.26-0241. This document can be accessed on the official website. For more details, please refer to the complete article on Benzinga.com.